Developer docs
API playgroundTry for free, no card

Search company profiles

Alora Pharmaceutical

Full company profile

uuid0007c4r

Namestring
Alora Pharmaceutical
Legal namestring
Alora Pharmaceuticals, LLC
Websiteurl
alorapharma.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Alora Pharmaceuticals, LLC is a privately held U.S. specialty pharmaceutical holding company headquartered in Alpharetta, Georgia. Founded in 2007, the company operates seven wholly-owned subsidiaries (Acella, Avion, Neuvosyn, Osmotica, Sovereign, Trigen, and Vertical) that develop, manufacture, and commercialize branded and generic prescription pharmaceuticals across seven therapeutic areas: women's health, endocrinology, neurology, dermatology, hematology, cough and cold, and pain management. Its branded portfolio includes NP Thyroid (#1 prescribed desiccated thyroid extract in the U.S.), DHIVY (first and only functionally scored carbidopa/levodopa tablet for Parkinson's disease), Relexxii (once-daily methylphenidate for ADHD using the proprietary Osmodex drug delivery platform), and a prenatal vitamin family across multiple sub-brands.

The company's commercial model is anchored by a specialty pharma field sales force engaging prescribers (neurologists, endocrinologists, women's health specialists) combined with U.S. retail/wholesale pharmacy distribution and Group Purchasing Organization contract relationships. Revenue is generated through (1) prescription pharmaceutical sales (branded and generic) across the portfolio, and (2) contract development and manufacturing organization (CDMO) services through Sovereign Pharmaceuticals (Fort Worth, TX) and Osmotica (Marietta, GA), with a combined manufacturing footprint exceeding 300,000 sq. ft. after the January 2022 Monarch PCM acquisition. Distribution is exclusively U.S.-domestic. Growth has been driven by a combination of strategic acquisitions (Sovereign 2019, Osmotica 2021, Monarch 2022), licensing agreements (Cenestin with Aspen Pharma, 2020), and organic new product launches, including FDA approvals and Phase II clinical pipeline progress for the investigational North Star DTE.

Short descriptiontext

Alora Pharmaceuticals is a privately held U.S. specialty pharmaceutical holding company operating seven subsidiaries that develop, manufacture, and commercialize branded and generic prescription drugs across seven therapeutic areas—including women's health, endocrinology, and neurology—via a field sales force, U.S. retail/wholesale distribution, and CDMO services.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersAlpharetta, United States
HQ citystring
Alpharetta
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, branded generics, pharmaceutical manufacturing, CDMO services, prescription drugs
Industry4 codes
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAD
Oral Solid Dose (OSD) Generics
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Prescription Pharmaceutical Sales
TypeOne Time License
Description

Revenue generated from sale of branded and generic prescription pharmaceutical products across multiple therapeutic areas including women's health, endocrinology, neurology, dermatology, and pediatrics

alorapharma.com
2Contract Manufacturing Services
TypeProfessional Services
Description

CDMO (Contract Development and Manufacturing Organization) services provided through Sovereign Pharmaceuticals and Osmotica, offering formulation, manufacturing, and packaging capabilities to third-party pharmaceutical companies

alorapharma.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Alora Pharmaceuticals develops, manufactures, and commercializes branded and generic specialty pharmaceutical products across women's health, endocrinology, neurology, dermatology, hematology, cough & cold, and pain management therapeutic areas. The company operates through seven subsidiaries serving patients with essential medicines while also providing CDMO (contract development and manufacturing organization) services through its Sovereign Pharmaceuticals and Osmotica subsidiaries. The product portfolio spans 90+ products including branded leaders such as NP Thyroid, DHIVY, Relexxii, and Cenestin, manufactured at over 300,000 sq. ft. of US-based facilities.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • NP Thyroid is the #1 prescribed desiccated thyroid extract in the United States by prescriptions filled
+2 more records
Product overview1 text field

Alora Pharmaceuticals operates as a specialty pharmaceutical company with a multi-brand portfolio structure. The company encompasses seven subsidiaries (Acella, Avion, Neuvosyn, Osmotica, Sovereign, Trigen, and Vertical) that develop and commercialize pharmaceutical products across seven therapeutic areas: Women's Health (prenatal vitamins, contraceptives, menopause support), Endocrinology (hypothyroidism treatments), Neurology (Parkinson's disease, ADHD), Dermatology, Hematology, Cough & Cold, and Pain Management. Key products include NP Thyroid (desiccated thyroid extract for hypothyroidism), DHIVY (carbidopa/levodopa for Parkinson's disease), Relexxii (methylphenidate for ADHD), and various prenatal vitamins. The company also offers contract manufacturing services through Sovereign Pharmaceuticals and controlled drug delivery expertise through Osmotica. Manufacturing facilities are located in Texas and Georgia.

Product and service16 records
1NP Thyroid
CategoryEndocrinology
Description

Desiccated thyroid extract (DTE) prescription product for treatment of adults with primary hypothyroidism. NP Thyroid is the #1 prescribed desiccated thyroid extract in the United States based on prescriptions filled, serving approximately 1.5 million American hypothyroidism patients who rely on DTE products.

2DHIVY (carbidopa and levodopa)
CategoryNeurology
Description

First and only functionally scored carbidopa/levodopa prescription tablet for Parkinson's disease treatment, designed to be divided for precise dosing. Each tablet's four segments contain 6.25/25 mg of CD/LD, enabling neurologists and movement disorder specialists to titrate dosing more precisely than with conventional carbidopa/levodopa tablets.

3Relexxii (methylphenidate hydrochloride extended-release tablets)
CategoryNeurology
Description

Once-daily methylphenidate hydrochloride extended-release tablet for treatment of ADHD in adults and pediatric patients 6 years and older. Uses proprietary Osmodex Drug Delivery Technology for controlled release throughout the day. Available in 7 flexible dosing options (18-mg to 72-mg). Relexxii is the largest US manufacturer of methylphenidate medications, addressing ongoing ADHD medication shortages.

4Balcoltra (Low Dose Birth Control)
CategoryWomen's Health
Description

Low-dose oral contraceptive product for women's health, indicated for pregnancy prevention.

5Divigel (Menopause Support)
CategoryWomen's Health
Description

Hormone therapy product for management of moderate to severe menopause symptoms in women.

6Cenestin (synthetic conjugated estrogens, A)
CategoryWomen's Health
Description

Plant-derived mixture of 9 conjugated estrogens indicated for treatment of moderate to severe vasomotor symptoms and moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. Available in 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, and 1.25 mg strengths.

7Acella Rx Prenatal Supplements
CategoryWomen's Health
Description

Prescription prenatal vitamin dietary supplements under the Acella brand for women's health, supporting pregnancy and prenatal nutritional needs.

8Avion Rx Prenatal Supplements
CategoryWomen's Health
Description

Prescription prenatal vitamin dietary supplements under the Avion brand for women's health.

9Vertical Rx Prenatal Supplements
CategoryWomen's Health
Description

Prescription prenatal vitamin dietary supplements under the Vertical brand for women's health.

10Bromfed
CategoryCough & Cold
Description

Antihistamine, decongestant, and cough suppressant prescription product for cough & cold symptom relief.

11Prenate Vitamin Family
CategoryWomen's Health
Description

Branded prenatal vitamin product line covering multiple formulations for women's reproductive health and pregnancy support.

12CDMO Services (Sovereign Pharmaceuticals)
CategoryPharmaceutical Manufacturing Services
Description

Contract Development and Manufacturing Organization (CDMO) services offered to third-party pharmaceutical companies, covering formulation, manufacturing, and packaging across solid, semi-solid, and liquid dosage forms with over 300,000 sq. ft. of US-based manufacturing capacity.

13CDMO Services (Osmotica - Controlled Drug Delivery)
CategoryPharmaceutical Manufacturing Services
Description

Contract Development and Manufacturing Organization services specializing in controlled and modified drug delivery systems, offered to third-party pharmaceutical clients leveraging proprietary Osmodex drug delivery technology.

14Hematology Products
CategoryHematology
Description

Pharmaceutical products for hematologic conditions, including treatments under the Avion Pharmaceuticals subsidiary.

15Pain Management Products
CategoryPain Management
Description

Pharmaceutical products for pain management, available through Acella Pharmaceuticals and Vertical Pharmaceuticals subsidiaries.

16Dermatology Products
CategoryDermatology
Description

Prescription dermatology products available through Acella and Avion Pharmaceuticals subsidiaries.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-05-20
Description

Vertical Pharmaceuticals, an Alora company, partnered with Medfinder to help patients prescribed Relexxii (ADHD medication) locate pharmacies with available inventory during ongoing medication shortages. The partnership offers patients Medfinder's AI-enabled pharmacy search service at no cost.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-22
Description

Acella Pharmaceuticals partnered with Paloma Health, a virtual medical practice treating hypothyroidism and Hashimoto's disease, to connect patients with NP Thyroid prescription options through Paloma's telehealth platform.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2020-11-12
Description

Avion Pharmaceuticals entered a license and commercialization agreement with Aspen Pharma USA Inc. and Aspen Global Incorporated for exclusive rights to relaunch Cenestin (synthetic conjugated estrogens A) tablets in the United States.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Established small-molecule CDMO offering formulation, manufacturing, and packaging services; relevant benchmark for Alora's Sovereign and Osmotica CDMO business lines.

TypeBroad incumbent
Description

Specialty pharmaceutical manufacturer with branded and generic franchises plus in-house CDMO-like operations; broader but comparable in vertical integration and dosage-form breadth.

TypeDirect peer
Description

Private specialty and generic pharmaceutical company with US manufacturing footprint, focused on niche therapeutic areas and women's health — a closely comparable mid-market specialty pharma.

TypeDirect peer
Description

Private specialty and generic pharmaceutical CDMO with solid oral dose capabilities; comparable mid-sized US manufacturer serving similar third-party contract manufacturing customers.

TypeDirect peer
Description

Specialty generics and branded pharmaceutical manufacturer with similar therapeutic breadth across women's health, neurology, and endocrinology, and a comparable US-focused operating model.

TypeBroad incumbent
Description

Larger specialty pharma with branded and generic portfolios across women's health, neurology, and pain management; competes across multiple Alora therapeutic areas with broader resources.

7Padagis
TypeDirect peer
Description

Specialty and generic pharmaceutical company with US manufacturing, distribution, and CDMO capabilities serving similar institutional and retail channels.

TypeDirect peer
Description

US-based manufacturer of generic and specialty pharmaceuticals with solid oral dose capabilities; comparable in scale and portfolio mix of branded niche plus high-volume generics.

TypeDirect peer
Description

Vertically integrated generic and specialty pharma with branded, generic, and CDMO offerings across multiple dosage forms; closest large-scale analog to Alora's portfolio and manufacturing strategy.

TypeDirect peer
Description

Specialty pharma with branded CNS products including ADHD and neurology franchises, leveraging proprietary drug delivery technology — analogous to Alora's Osmodex-enabled Relexxii strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries8 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alora Pharmaceutical

Specialty Pharmaceuticalsalorapharma.com

Alora Pharmaceuticals is a privately held U.S. specialty pharmaceutical holding company operating seven subsidiaries that develop, manufacture, and commercialize branded and generic prescription drugs across seven therapeutic areas—including women's health, endocrinology, and neurology—via a field sales force, U.S. retail/wholesale distribution, and CDMO services.

What Alora Pharmaceutical does

Alora Pharmaceuticals, LLC is a privately held U.S. specialty pharmaceutical holding company headquartered in Alpharetta, Georgia. Founded in 2007, the company operates seven wholly-owned subsidiaries (Acella, Avion, Neuvosyn, Osmotica, Sovereign, Trigen, and Vertical) that develop, manufacture, and commercialize branded and generic prescription pharmaceuticals across seven therapeutic areas: women's health, endocrinology, neurology, dermatology, hematology, cough and cold, and pain management. Its branded portfolio includes NP Thyroid (#1 prescribed desiccated thyroid extract in the U.S.), DHIVY (first and only functionally scored carbidopa/levodopa tablet for Parkinson's disease), Relexxii (once-daily methylphenidate for ADHD using the proprietary Osmodex drug delivery platform), and a prenatal vitamin family across multiple sub-brands.

The company's commercial model is anchored by a specialty pharma field sales force engaging prescribers (neurologists, endocrinologists, women's health specialists) combined with U.S. retail/wholesale pharmacy distribution and Group Purchasing Organization contract relationships. Revenue is generated through (1) prescription pharmaceutical sales (branded and generic) across the portfolio, and (2) contract development and manufacturing organization (CDMO) services through Sovereign Pharmaceuticals (Fort Worth, TX) and Osmotica (Marietta, GA), with a combined manufacturing footprint exceeding 300,000 sq. ft. after the January 2022 Monarch PCM acquisition. Distribution is exclusively U.S.-domestic. Growth has been driven by a combination of strategic acquisitions (Sovereign 2019, Osmotica 2021, Monarch 2022), licensing agreements (Cenestin with Aspen Pharma, 2020), and organic new product launches, including FDA approvals and Phase II clinical pipeline progress for the investigational North Star DTE.

Alora Pharmaceutical firmographics

Firmographics
Name
Alora Pharmaceutical
Legal name
Alora Pharmaceuticals, LLC
Website
https://alorapharma.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
101–250 employees
Short description
Alora Pharmaceuticals is a privately held U.S. specialty pharmaceutical holding company operating seven subsidiaries that develop, manufacture, and commercialize branded and generic prescription drugs across seven therapeutic areas—including women's health, endocrinology, and neurology—via a field sales force, U.S. retail/wholesale distribution, and CDMO services.
Ownership category
akta.pro rank

Alora Pharmaceutical industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAD
Oral Solid Dose (OSD) Generics
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)

Keywords

  • Specialty pharmaceuticals
  • Branded generics
  • Pharmaceutical manufacturing
  • CDMO services
  • Prescription drugs

Where Alora Pharmaceutical is headquartered

Location

Headquarters

HQ city
Alpharetta
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Alora Pharmaceutical business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Prescription Pharmaceutical Sales: Revenue generated from sale of branded and generic prescription pharmaceutical products across multiple therapeutic areas including women's health, endocrinology, neurology, dermatology, and pediatrics
  2. Contract Manufacturing Services: CDMO (Contract Development and Manufacturing Organization) services provided through Sovereign Pharmaceuticals and Osmotica, offering formulation, manufacturing, and packaging capabilities to third-party pharmaceutical companies

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Alora Pharmaceutical product offering

Product offering

Core offering

Alora Pharmaceuticals develops, manufactures, and commercializes branded and generic specialty pharmaceutical products across women's health, endocrinology, neurology, dermatology, hematology, cough & cold, and pain management therapeutic areas. The company operates through seven subsidiaries serving patients with essential medicines while also providing CDMO (contract development and manufacturing organization) services through its Sovereign Pharmaceuticals and Osmotica subsidiaries. The product portfolio spans 90+ products including branded leaders such as NP Thyroid, DHIVY, Relexxii, and Cenestin, manufactured at over 300,000 sq. ft. of US-based facilities.

Product overview

Alora Pharmaceuticals operates as a specialty pharmaceutical company with a multi-brand portfolio structure. The company encompasses seven subsidiaries (Acella, Avion, Neuvosyn, Osmotica, Sovereign, Trigen, and Vertical) that develop and commercialize pharmaceutical products across seven therapeutic areas: Women's Health (prenatal vitamins, contraceptives, menopause support), Endocrinology (hypothyroidism treatments), Neurology (Parkinson's disease, ADHD), Dermatology, Hematology, Cough & Cold, and Pain Management. Key products include NP Thyroid (desiccated thyroid extract for hypothyroidism), DHIVY (carbidopa/levodopa for Parkinson's disease), Relexxii (methylphenidate for ADHD), and various prenatal vitamins. The company also offers contract manufacturing services through Sovereign Pharmaceuticals and controlled drug delivery expertise through Osmotica. Manufacturing facilities are located in Texas and Georgia.

Differentiator

Problem solved

Functional benefit

Products and services

  • NP Thyroid Desiccated thyroid extract (DTE) prescription product for treatment of adults with primary hypothyroidism. NP Thyroid is the #1 prescribed desiccated thyroid extract in the United States based on prescriptions filled, serving approximately 1.5 million American hypothyroidism patients who rely on DTE products.
  • DHIVY (carbidopa and levodopa) First and only functionally scored carbidopa/levodopa prescription tablet for Parkinson's disease treatment, designed to be divided for precise dosing. Each tablet's four segments contain 6.25/25 mg of CD/LD, enabling neurologists and movement disorder specialists to titrate dosing more precisely than with conventional carbidopa/levodopa tablets.
  • Relexxii (methylphenidate hydrochloride extended-release tablets) Once-daily methylphenidate hydrochloride extended-release tablet for treatment of ADHD in adults and pediatric patients 6 years and older. Uses proprietary Osmodex Drug Delivery Technology for controlled release throughout the day. Available in 7 flexible dosing options (18-mg to 72-mg). Relexxii is the largest US manufacturer of methylphenidate medications, addressing ongoing ADHD medication shortages.
  • Balcoltra (Low Dose Birth Control) Low-dose oral contraceptive product for women's health, indicated for pregnancy prevention.
  • Divigel (Menopause Support) Hormone therapy product for management of moderate to severe menopause symptoms in women.
  • Cenestin (synthetic conjugated estrogens, A) Plant-derived mixture of 9 conjugated estrogens indicated for treatment of moderate to severe vasomotor symptoms and moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. Available in 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, and 1.25 mg strengths.
  • Acella Rx Prenatal Supplements Prescription prenatal vitamin dietary supplements under the Acella brand for women's health, supporting pregnancy and prenatal nutritional needs.
  • Avion Rx Prenatal Supplements Prescription prenatal vitamin dietary supplements under the Avion brand for women's health.
  • Vertical Rx Prenatal Supplements Prescription prenatal vitamin dietary supplements under the Vertical brand for women's health.
  • Bromfed Antihistamine, decongestant, and cough suppressant prescription product for cough & cold symptom relief.
  • Prenate Vitamin Family Branded prenatal vitamin product line covering multiple formulations for women's reproductive health and pregnancy support.
  • CDMO Services (Sovereign Pharmaceuticals) Contract Development and Manufacturing Organization (CDMO) services offered to third-party pharmaceutical companies, covering formulation, manufacturing, and packaging across solid, semi-solid, and liquid dosage forms with over 300,000 sq. ft. of US-based manufacturing capacity.
  • CDMO Services (Osmotica - Controlled Drug Delivery) Contract Development and Manufacturing Organization services specializing in controlled and modified drug delivery systems, offered to third-party pharmaceutical clients leveraging proprietary Osmodex drug delivery technology.
  • Hematology Products Pharmaceutical products for hematologic conditions, including treatments under the Avion Pharmaceuticals subsidiary.
  • Pain Management Products Pharmaceutical products for pain management, available through Acella Pharmaceuticals and Vertical Pharmaceuticals subsidiaries.
  • Dermatology Products Prescription dermatology products available through Acella and Avion Pharmaceuticals subsidiaries.

Quantifiable outcome

  • NP Thyroid is the #1 prescribed desiccated thyroid extract in the United States by prescriptions filled
  • +2 more outcomes

Companies that use Alora Pharmaceutical

Customer profile

Named customers5 records

Segments6 records

Ideal customer profiles2 records

Alora Pharmaceutical technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Alora Pharmaceutical partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • MedfindercoreGTM or Marketing Partner · 20 May 2026Vertical Pharmaceuticals, an Alora company, partnered with Medfinder to help patients prescribed Relexxii (ADHD medication) locate pharmacies with available inventory during ongoing medication shortages. The partnership offers patients Medfinder's AI-enabled pharmacy search service at no cost.
  • Paloma HealthcoreStrategic or Co-development Partner · 22 October 2024Acella Pharmaceuticals partnered with Paloma Health, a virtual medical practice treating hypothyroidism and Hashimoto's disease, to connect patients with NP Thyroid prescription options through Paloma's telehealth platform.
  • Aspen Pharma (Aspen Pharmacare Holdings Limited)coreOEM/ Whitelabel/ Licensing Partner · 12 November 2020Avion Pharmaceuticals entered a license and commercialization agreement with Aspen Pharma USA Inc. and Aspen Global Incorporated for exclusive rights to relaunch Cenestin (synthetic conjugated estrogens A) tablets in the United States.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Alora Pharmaceutical competitors and assessment

Company assessment

Broad incumbents

  • Cambrex: Established small-molecule CDMO offering formulation, manufacturing, and packaging services; relevant benchmark for Alora's Sovereign and Osmotica CDMO business lines.
  • Mallinckrodt Pharmaceuticals: Specialty pharmaceutical manufacturer with branded and generic franchises plus in-house CDMO-like operations; broader but comparable in vertical integration and dosage-form breadth.
  • Endo Pharmaceuticals: Larger specialty pharma with branded and generic portfolios across women's health, neurology, and pain management; competes across multiple Alora therapeutic areas with broader resources.

Direct peers

  • Upsher-Smith Laboratories: Private specialty and generic pharmaceutical company with US manufacturing footprint, focused on niche therapeutic areas and women's health — a closely comparable mid-market specialty pharma.
  • Novitium Pharma: Private specialty and generic pharmaceutical CDMO with solid oral dose capabilities; comparable mid-sized US manufacturer serving similar third-party contract manufacturing customers.
  • ANI Pharmaceuticals: Specialty generics and branded pharmaceutical manufacturer with similar therapeutic breadth across women's health, neurology, and endocrinology, and a comparable US-focused operating model.
  • Padagis: Specialty and generic pharmaceutical company with US manufacturing, distribution, and CDMO capabilities serving similar institutional and retail channels.
  • Lannett Company: US-based manufacturer of generic and specialty pharmaceuticals with solid oral dose capabilities; comparable in scale and portfolio mix of branded niche plus high-volume generics.
  • Amneal Pharmaceuticals: Vertically integrated generic and specialty pharma with branded, generic, and CDMO offerings across multiple dosage forms; closest large-scale analog to Alora's portfolio and manufacturing strategy.
  • Supernus Pharmaceuticals: Specialty pharma with branded CNS products including ADHD and neurology franchises, leveraging proprietary drug delivery technology — analogous to Alora's Osmodex-enabled Relexxii strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Alora Pharmaceutical social profiles

Digital presence

Alora Pharmaceutical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alora Pharmaceutical leadership team

Management profile

Number of profiles

Profiles10 records

Alora Pharmaceutical subsidiaries and ownership

Company hierarchy

Subsidiaries8 records

Alora Pharmaceutical funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alora Pharmaceutical M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alora Pharmaceutical

What does Alora Pharmaceutical do?

Alora Pharmaceuticals develops, manufactures, and commercializes branded and generic specialty pharmaceutical products across women's health, endocrinology, neurology, dermatology, hematology, cough & cold, and pain management therapeutic areas. The company operates through seven subsidiaries serving patients with essential medicines while also providing CDMO (contract development and manufacturing organization) services through its Sovereign Pharmaceuticals and Osmotica subsidiaries. The product portfolio spans 90+ products including branded leaders such as NP Thyroid, DHIVY, Relexxii, and Cenestin, manufactured at over 300,000 sq. ft. of US-based facilities.

Is Alora Pharmaceutical a public or private company?

Alora Pharmaceutical is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Alora Pharmaceutical founded?

Alora Pharmaceutical was founded in 2007. It employs 101 to 250 people.

Where is Alora Pharmaceutical based?

Alora Pharmaceutical is headquartered in Alpharetta, United States, in the North America region.

How does Alora Pharmaceutical make money?

Two revenue lines are on record. Prescription Pharmaceutical Sales are the primary driver. The others are contract Manufacturing Services.

Who are Alora Pharmaceutical's main competitors?

Broad incumbents on record are Cambrex, Mallinckrodt Pharmaceuticals and Endo Pharmaceuticals. Direct peers are Upsher-Smith Laboratories, Novitium Pharma, ANI Pharmaceuticals, Padagis, Lannett Company, Amneal Pharmaceuticals and Supernus Pharmaceuticals.

Does Alora Pharmaceutical have an API?

No public API is recorded for Alora Pharmaceutical.

What industry is Alora Pharmaceutical in?

Alora Pharmaceutical's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAIABAD, Oral Solid Dose (OSD) Generics. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireVertical Pharmaceuticals Partners with Medfinder to Help Patients Find Relexxii® During Ongoing ADHD Medication ShortagesVertical Pharmaceuticals partnered with Medfinder to help patients find pharmacies with Relexxii inventory during ADHD medication shortages. The partnership is free for patients, and Medfinder has processed over 18,000 Relexxii pharmacy stock checks since launch.AlorapharmaAlora Pharmaceuticals Celebrates Acquisition of Monarch Manufacturing FacilitySovereign Pharmaceuticals, LLC, a wholly owned subsidiary of Alora Pharmaceuticals, acquired substantially all of Monarch PCM, LLC's manufacturing capabilities located in Fort Worth, TX through bankruptcy proceedings on January 4, 2022. The acquisition adds 60,000 square feet of manufacturing space, bringing Alora's total footprint to over 300,000 square feet, and adds 48 employees while enhancing capabilities in solid, semi-solid, and liquid manufacturing. The deal is positioned as a strategic move to expand contract manufacturing volume and capabilities for Alora and its partners.PR NewswireNew Data Confirms Bioequivalence of Relexxii® and Concerta® in Healthy Adults¹Alora Pharmaceuticals announced publication of a pivotal pharmacokinetic study in Clinical Pharmacology in Drug Development demonstrating bioequivalence between its Relexxii (methylphenidate hydrochloride extended-release tablets) and the reference product Concerta® for ADHD treatment. The two replicate crossover studies in healthy adults confirmed statistical bioequivalence across key parameters including Cmax and AUC measurements at multiple time intervals. Relexxii uses an osmotic pump delivery system mirroring the reference product's mechanism, and represents the only branded methylphenidate HCI ER tablet offering 45 mg and 63 mg strengths.MorningstarJackie Ranke and Becky Clasper of Alora Pharmaceuticals Honored as Healthcare Businesswomen's Association Award WinnersJackie Ranke and Becky Clasper of Alora Pharmaceuticals will be honored at the Healthcare Businesswomen's Association's annual Woman of the Year celebration in Chicago on May 9, 2025. Ranke will receive a Luminary award for her 20+ years of leadership, while Clasper will be named Rising Star for her work in quality and compliance.PR NewswireAcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAcelRx Pharmaceuticals reported a Q2 2023 net loss of $4.4 million while completing a $10 million private placement capital raise (with potential additional $16.3 million), fully repaying its senior debt with Oxford, and awaiting FDA response on an Emergency Use Authorization submission for Niyad made in April. The company also completed the divestment of its DSUVIA drug to Alora Pharmaceuticals in April, retaining a 15% royalty on commercial sales and a 75% royalty on Department of Defense sales, plus up to $116.5 million in sales-based milestones. AcelRx expects to initiate a registrational study for Niyad in Q4 2023 with a data readout anticipated for mid-2024.PR NewswireAcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate UpdateAcelRx Pharmaceuticals reported Q1 2023 financial results on May 10, 2023, showing a net loss of $8.2 million or $0.75 per share, compared to a net loss of $8.7 million or $1.19 per share in Q1 2022. The company announced two key corporate developments: submission of an Emergency Use Authorization request for Niyad to the FDA on April 27, 2023, and the closing of the DSUVIA divestment to Alora Pharmaceuticals on April 3, 2023, which provides AcelRx with a 15% royalty on commercial sales and up to $116.5 million in sales-based milestones. The company ended Q1 2023 with $13.4 million in cash.BioSpaceAcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora PharmaceuticalsAcelRx Pharmaceuticals divested its FDA-approved drug DSUVIA to Alora Pharmaceuticals, with closing expected by month-end. The deal includes 15% royalties on commercial sales, 75% on DoD sales, and up to $116.5 million in milestones. AcelRx will focus on its lead nafamostat program Niyad, with an EUA submission expected in Q2 2023.PR NewswireAcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora PharmaceuticalsAcelRx Pharmaceuticals announced the divestment of its FDA-approved drug DSUVIA to Alora Pharmaceuticals, with closing expected by the end of March. The deal includes 15% royalties on commercial sales, 75% on DoD sales, and up to $116.5 million in milestones. AcelRx will focus on its lead nafamostat program Niyad, with an EUA submission expected in Q2 2023.PR NewswireAlora Pharmaceuticals Celebrates Acquisition of Monarch Manufacturing FacilityAlora Pharmaceuticals' wholly owned subsidiary Sovereign Pharmaceuticals acquired Monarch PCM's manufacturing capabilities through bankruptcy proceedings on January 4, 2022, located in Fort Worth, TX. The acquisition includes equipment and leased space adjacent to Sovereign's existing facility, adding 60,000 square feet of manufacturing space and 48 employees. The deal is expected to significantly expand Alora's manufacturing capabilities in solid, semi-solid, and liquid production, increasing the company's total manufacturing footprint to over 300,000 square feet.PR NewswireAvion Pharmaceuticals, LLC, an Alora Pharmaceuticals company, announces the FDA approval and availability of DHIVY™ for the treatment of Parkinson's diseaseAvion Pharmaceuticals, an Alora Pharmaceuticals company, announced the commercial launch of DHIVY, the first and only functionally fractional carbidopa/levodopa (CD/LD) tablet for Parkinson's disease, following FDA approval received in November 2021. The tablet's unique design features deep scores allowing precise division into 6.25/25 mg increments—the smallest available dose—to help physicians better individualize treatment and address motor fluctuations and dyskinesia. Parkinson's disease affects an estimated 1.04 million individuals in the United States with prevalence projected to reach 1.64 million by 2037, making CD/LD the fastest-growing neurological condition in the country.